Lisata Therapeutics AI Stock Analysis
Want to see LSTA full AI Analyst Report?
Lisata Therapeutics (LSTA) AI Stock Analysis
Lisata Therapeutics
(NASDAQ:LSTA)
The score is held down primarily by weak financial performance (minimal revenue, large losses, and sustained cash burn despite zero debt). Technicals are mixed with only short-term improvement against a longer-term downtrend, and valuation is constrained by negative earnings and no provided dividend yield. Offsetting these, recent corporate actions (M&A plus ~$225M financing and governance upgrades) materially improve funding runway and strategic positioning but do not remove near-term execution and dilution risk.
Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.90M
- Dividend Yield
- ―
- Average Volume (3M)
- 304.44K
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- 0.27
- Revenue Growth
- -90.65%
- EPS Growth
- 11.37%
- Country
- US
- Employees
- 21
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lisata Therapeutics Business Overview & Revenue Model
Company Description
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissu...
Lisata Therapeutics Earnings Call Summary
Lisata Therapeutics has made significant progress in its clinical programs and strategic partnerships, reflecting strong operational management and promising trial results. However, the need for additional capital for Phase III trials poses a significant challenge. The market's lack of response to positive developments highlights ongoing investor skepticism or broader market conditions.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. They reported a decrease in operating expenses to $4.4 million for the third quarter of 2025, down from $5.3 million in the same period the previous year, marking a 17.3% reduction. Research and development expenses also declined by 22.9% to $2 million. The company reported a net loss of $4.2 million, compared to $4.9 million in the third quarter of 2024. Lisata highlighted their cash and cash equivalents totaling approximately $19 million as of September 30, 2025, with projections to support operations into the first quarter of 2027. Additionally, they discussed their strategic alliance with GATC Health and a nonexclusive global license agreement with Catalent, indicating a promising period ahead with several anticipated milestones.
Lisata Therapeutics Financial Statement Overview
Summary
Financials reflect an early-stage, cash-burning biotech: TTM revenue is extremely small (~$0.1M) with a large net loss (~$17.2M) and negative operating/free cash flow (about -$21.7M TTM). Balance-sheet debt is $0 (a positive), but equity has eroded sharply over time (down to ~$7.6M TTM), indicating ongoing losses and funding dependence.
Income Statement
12Very NegativeBalance Sheet
35NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.00K | 170.00K | 1.00M | 0 | 0 | 0 |
| Gross Profit | 91.00K | 24.00K | 1.00M | 0 | 0 | 0 |
| EBITDA | -21.83M | -17.40M | -20.61M | -22.98M | -56.63M | -28.92M |
| Net Income | -17.16M | -16.59M | -19.98M | -20.84M | -54.23M | -27.47M |
Balance Sheet | ||||||
| Total Assets | 648.41M | 17.74M | 35.00M | 54.69M | 73.03M | 97.01M |
| Cash, Cash Equivalents and Short-Term Investments | 282.72M | 15.96M | 31.25M | 50.53M | 69.23M | 94.97M |
| Total Debt | 0 | 0 | 137.00K | 168.00K | 485.00K | 714.00K |
| Total Liabilities | 56.77M | 3.14M | 5.68M | 6.80M | 6.71M | 5.01M |
| Stockholders Equity | 7.64M | 14.86M | 29.57M | 48.15M | 66.58M | 92.25M |
Cash Flow | ||||||
| Free Cash Flow | -21.66M | -15.98M | -19.36M | -20.03M | -21.45M | -22.30M |
| Operating Cash Flow | -21.66M | -15.95M | -19.36M | -20.03M | -21.17M | -22.25M |
| Investing Cash Flow | 72.92M | 15.09M | 13.23M | 10.10M | 28.91M | -54.90M |
| Financing Cash Flow | 212.48M | 599.00K | -206.00K | 385.00K | -224.00K | 85.28M |
Lisata Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Neutral. The current price of 1.21 is above the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.28, and below the 200-day MA of 2.86, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 54.08 is Neutral, neither overbought nor oversold. The STOCH value of 55.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LSTA.
Lisata Therapeutics Risk Analysis
Lisata Therapeutics disclosed 83 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksLisata Therapeutics Peers Comparison
Overall Rating
PCSA55Neutral
LSTA49Neutral
CTXR43Neutral
APVO41Neutral
APLM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $5.20M | -0.03 | -411.08% | ― | ― | -92.15% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $13.07M | -0.64 | -164.72% | ― | -90.65% | 11.37% | |
| 43Neutral | $14.69M | -0.25 | -67.15% | ― | ― | 57.48% | |
| 41Neutral | $1.08M | -0.00 | -201.49% | ― | ― | 99.41% | |
| 37Underperform | $51.54M | -68.00 | 103.09% | ― | -100.00% | 99.08% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LSTA | Lisata Therapeutics, Inc. | 1.21 | -0.88 | -42.11% | |
| APVO | Aptevo | 0.59 | -24.07 | -97.59% | |
| CTXR | Citius Pharma | 0.54 | -0.40 | -42.78% | |
| PCSA | Processa Pharmaceuticals, Inc. | 1.86 | -4.98 | -72.81% | |
| APLM | Apollomics Inc. | 17.68 | -3.77 | -17.58% |
Lisata Therapeutics Corporate Events
Lisata Therapeutics Stockholders Approve Equity Plans, Defer Conversion Vote
NeutralOn November 9, 2026, Lisata Therapeutics stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. The plans reserved 44,764,472 and 3,730,372 common shares, respectively, with specified automatic increases, while th...
Lisata Therapeutics Expands Board, Appoints Independent Director
PositiveOn October 13, 2026, Lisata Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed veteran biopharma executive Jeffrey Farrow as a Class III director, with his initial term running through the 2028 annual meeting...
Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio
PositiveOn September 17, 2026, Lisata Therapeutics completed a stock‑for‑stock acquisition of Marea Therapeutics, making Marea’s cardioendocrine portfolio the strategic focus of the combined company. The deal significantly reshapes Lisata’s shareholder base,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
